Evaluating Thera-101 as a Low-Volume Resuscitation Fluid in a Model of Polytrauma
Abstract
Traumatic brain injury (TBI) and hemorrhage remain challenging to treat in austere conditions. Developing a therapeutic to mitigate the associated pathophysiology is critical to meet this treatment gap, especially as these injuries and associated high mortality are possibly preventable. Here, Thera-101 (T-101) was evaluated as low-volume resuscitative fluid in a rat model of TBI and hemorrhage. The therapeutic, T-101, is uniquely situated as a TBI and hemorrhage intervention. It contains a cocktail of proteins and microvesicles from the secretome of adipose-derived mesenchymal stromal cells that can act on repair and regenerative mechanisms associated with poly-trauma. T-101 efficacy was determined at 4, 24, 48, and 72 h post-injury by evaluating blood chemistry, inflammatory chemo/cytokines, histology, and diffusion tensor imaging. Blood chemistry indicated that T-101 reduced the markers of liver damage to Sham levels while the levels remained elevated with the control (saline) resuscitative fluid. Histology supports the potential protective effects of T-101 on the kidneys. Diffusion tensor imaging showed that the injury caused the most damage to the corpus callosum and the fimbria. Immunohistochemistry suggests that T-101 may mitigate astrocyte activation at 72 h. Together, these data suggest that T-101 may serve as a potential field deployable low-volume resuscitation therapeutic.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Oct 21, 2022
- Source ID
- 10.3390/ijms232012664
Entities
People
- Alexander Burdette
- Annette R. Rodriguez
- Brian Johnstone
- Bridney Lundquist
- Heuy-ching Wang
- Jacob Glaser
- Jessica Stukel Shah
- Joseph Macaitis
- Michael F. Coleman
- Michelle A. Jefferson
- Sylvain Cardin
Organizations
- Congressionally Directed Medical Research Programs